Though more research is needed to understand who might benefit from GLP-1 agonists for addiction, early studies suggest that the approach holds promise.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood ...

A decision about how to spend settlement funds in Carter County, Kentucky, which was hit hard by the opioid epidemic, offers ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

Researchers have debunked key beliefs about addiction, like that a person must hit "rock bottom" before having treatment or ...

A psychiatrist from Washington University School of Medicine explains the difference between being addicted to a substance and taking a medication for a chronic condition. During Robert F. Kennedy Jr.

As the opioid crisis continues to challenge the Appalachian Highlands and communities nationwide, Ballad Health and East ...

President Donald Trump and HHS Secretary Robert F. Kennedy Jr. said they will be studying the "threat" to children posed by ...

Ozempic may also help people drink less alcohol. Primary care doctors are concerned about patients accessing GLP-1s through ...

Addiction affects more than just the individual struggling with substance abuse; it impacts the entire family. Loved ones ...

A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.

Research found that semaglutide, the active substance in Ozempic and the weight-loss drug Wegovy, could help curb alcohol ...